Zobrazeno 1 - 10 of 15 pro vyhledávání: '"Koen Van Der Borght"'
1
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
Autor: Christopher Chiu, Hugo Ceulemans, Torben Plesner, Greet Vanhoof, Jordan M. Schecter, Nizar J. Bahlis, Saad Z. Usmani, Tina Smets, Homer Adams, Andrew C. Lysaght, Yann Abraham, Hervé Avet-Loiseau, Jaime Bald, Frederik Stevenaert, Joshua Rusbuldt, Karl C. Nielsen, Amy Axel, Tuna Mutis, Tineke Casneuf, Inger S. Nijhof, Koen Van der Borght, Brad Foulk, Niels W.C.J. van de Donk
Publikováno v: Casneuf, T, Adams, H C, van de Donk, N W C J, Abraham, Y, Bald, J, Vanhoof, G, Van der Borght, K, Smets, T, Foulk, B, Nielsen, K C, Rusbuldt, J, Axel, A, Lysaght, A, Ceulemans, H, Stevenaert, F, Usmani, S Z, Plesner, T, Avet-Loiseau, H, Nijhof, I, Mutis, T, Schecter, J M, Chiu, C & Bahlis, N J 2021, ' Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab ', Leukemia, vol. 35, no. 2, pp. 573-584 . https://doi.org/10.1038/s41375-020-0855-4
Leukemia
Leukemia, 35(2), 573-584. Nature Publishing Group
Casneuf, T, Adams, H C, van de Donk, N W C J, Abraham, Y, Bald, J, Vanhoof, G, Van der Borght, K, Smets, T, Foulk, B, Nielsen, K C, Rusbuldt, J, Axel, A, Lysaght, A, Ceulemans, H, Stevenaert, F, Usmani, S Z, Plesner, T, Avet-Loiseau, H, Nijhof, I, Mutis, T, Schecter, J M, Chiu, C & Bahlis, N J 2021, ' Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab ', Leukemia, vol. 35, pp. 573-584 . https://doi.org/10.1038/s41375-020-0855-4
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune response, reducing natura
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6476f20835a97bd61e5db396f8b77608
https://research.vumc.nl/en/publications/534ff20f-4ef5-47f0-a75d-98f650c178d0
Zobrazit plný text záznamu
3
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
Autor: Torben Plesner, Saad Z. Usmani, Koen Van der Borght, Homer Adams, Greet Vanhoof, Amy Sasser, Henk M. Lokhorst, Tineke Casneuf, Jakub Krejcik, Inger S. Nijhof, Tina Smets, Christopher Chiu, Hugo Ceulemans, Sagar Lonial, Niels W.C.J. van de Donk, Tuna Mutis, Frederik Stevenaert, Yann Abraham, Jaime Bald
Publikováno v: Adams, H C, Stevenaert, F, Krejcik, J, Van der Borght, K, Smets, T, Bald, J, Abraham, Y, Ceulemans, H, Chiu, C, Vanhoof, G, Usmani, S Z, Plesner, T, Lonial, S, Nijhof, I, Lokhorst, H M, Mutis, T, van de Donk, N W C J, Sasser, A K & Casneuf, T 2019, ' High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action ', Cytometry. Part A, vol. 95, no. 3, pp. 279-289 . https://doi.org/10.1002/cyto.a.23693
Cytometry Part A, 95(3), 279-289
Adams, H C, Stevenaert, F, Krejcik, J, Van der Borght, K, Smets, T, Bald, J, Abraham, Y, Ceulemans, H, Chiu, C, Vanhoof, G, Usmani, S Z, Plesner, T, Lonial, S, Nijhof, I, Lokhorst, H M, Mutis, T, van de Donk, N W C J, Sasser, A K & Casneuf, T 2019, ' High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action ', Cytometry Part A, vol. 95, no. 3, pp. 279-289 . https://doi.org/10.1002/cyto.a.23693
Daratumumab is a CD38-targeted human monoclonal antibody with direct anti-myeloma cell mechanisms of action. Flow cytometry in relapsed and/or refractory multiple myeloma (RRMM) patients treated with daratumumab revealed cytotoxic T-cell expansion an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02b1d8fa08423cee70f92f2f3a32022b
https://findresearcher.sdu.dk:8443/ws/files/149065141/High_Parameter_Mass_Cytometry_Evaluation_of_....pdf
Zobrazit plný text záznamu
4
BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism
Autor: Rytis Bagdziunas, Olivier Thas, Heather Turner, Hugo Ceulemans, Bie Verbist, Koen Van der Borght, Annelies Tourny, Maxim Nazarov
Publikováno v: Scientific Reports
SCIENTIFIC REPORTS
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Clinical efficacy regularly requires the combination of drugs. For an early estimation of the clinical value of (potentially many) combinations of pharmacologic compounds during discovery, the observed combination effect is typically compared to that
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bb3735398062ae154423cd3511aa372
https://doi.org/10.1038/s41598-017-18068-5
Zobrazit plný text záznamu
5
VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering
Autor: Joke Reumers, Kim Thys, Olivier Thas, Yves Wetzels, Bie Verbist, Willem Talloen, Jeroen Aerssens, Koen Van der Borght, Lieven Clement
Publikováno v: Bioinformatics. 31:94-101
Motivation : In virology, massively parallel sequencing (MPS) opens many opportunities for studying viral quasi-species, e.g. in HIV-1- and HCV-infected patients. This is essential for understanding pathways to resistance, which can substantially imp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6af8d3414cd5786d0658b588461a0547
https://doi.org/10.1093/bioinformatics/btu587
Zobrazit plný text záznamu
6
A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype
Autor: Lee T. Bacheler, Koen Van Der Borght, Pierre Lecocq, Gaston Picchio, Margriet Van Houtte, Theresa Pattery
Publikováno v: Journal of Medical Virology. 81:1702-1709
Concordance between the conventional HIV-1 phenotypic drug resistance assay, PhenoSense (PS), and vircoTYPE HIV-1 (vT), a drug resistance assay based on prediction of the phenotype, was investigated in a data set from the Stanford HIV Resistance data
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cfbd12f9bb68e3459d03f42ae7dc049
https://doi.org/10.1002/jmv.21585
Zobrazit plný text záznamu
7
QQ-SNV: single nucleotide variant detection at low frequency by comparing the quality quantiles
Autor: Lieven Clement, Koen Van der Borght, Kim Thys, Yves Wetzels, Joke Reumers, Bie Verbist, Jeroen Aerssens, Herman van Vlijmen
Publikováno v: BMC BIOINFORMATICS
BMC Bioinformatics
Background Next generation sequencing enables studying heterogeneous populations of viral infections. When the sequencing is done at high coverage depth (“deep sequencing”), low frequency variants can be detected. Here we present QQ-SNV (http://s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e05faed92e3f1864a376e05bfaafb57
https://biblio.ugent.be/publication/7180089
Zobrazit plný text záznamu
8
Multi-model inference using mixed effects from a linear regression based genetic algorithm
Autor: Geert Verbeke, Herman van Vlijmen, Koen Van der Borght
Publikováno v: BMC Bioinformatics
Background: Different high-dimensional regression methodologies exist for the selection of variables to predict a continuous variable. To improve the variable selection in case clustered observations are present in the training data, an extension tow
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecb05857f22838ffdfc7d32117be109c
http://hdl.handle.net/1942/16866
Zobrazit plný text záznamu
10
Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling
Autor: Ann Verheyen, Herman W. T. van Vlijmen, Maxim Feyaerts, Koen Van Der Borght, Elke Van Craenenbroeck, Yvan Verlinden, Liesbeth Van Wesenbeeck
Publikováno v: Virology Journal, Vol 10, Iss 1, p 8 (2013)
Virology Journal
Virology Journal; Vol 10
Background Integrase inhibitors (INI) form a new drug class in the treatment of HIV-1 patients. We developed a linear regression modeling approach to make a quantitative raltegravir (RAL) resistance phenotype prediction, as Fold Change in IC50 agains
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::229e398bc80c3548fafe9834ac4bea62
http://www.virologyj.com/content/10/1/8
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje